Aktis Oncology, Inc. (AKTS) vs Nuvalent Inc (NUVL)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| AKTS | NUVL | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Size band | SMALL | MID |
| Listing | Nasdaq GS | Nasdaq GM |
| Country | United States | United States |
| Theme | oncology | oncology |
| Price and returns | ||
| Last close | $15.73 | $123.96 |
| Return · 1 week | +4.10% | 0.00% |
| Return · 1 month | −18.71% | 0.00% |
| Return · 3 months | −31.52% | 0.00% |
| Return · year to date | −29.78% | +22.93% |
| Return · 1 year | −29.78% | +26.87% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −53.99% | −0.02% |
| 52-week high | $34.19 | $123.99 |
| 52-week low | $14.72 | $87.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $874.89M | $9.79B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $4.60M | $149.69M |
| Employees | 79 | 234 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | n/a (negative forward earnings) |
| Price to sales | 86.97× | — |
| Price to book | 1.79× | 8.33× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | — |
| Enterprise value to revenue | 36.66× | — |
| Earnings per share · trailing | -1.70 | -6.06 |
| Profitability | ||
| Operating margin | −853.99% | 0.00% |
| Profit margin | −727.04% | — |
| Return on equity | — | −41.19% |
| Return on assets | — | −22.51% |
| Growth | ||
| Revenue growth | +111.40% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 2.32 | — |
| Current ratio | 16.33 | 16.14 |
| Dividend yield | 0.00% | — |
| Payout ratio | — | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 31.43 | — |
| ADX · 14 | 42.35 | — |
| 50-day average | $21.23 | — |
| 200-day average | $21.12 | — |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 5.75% | — |
The full AKTS analysis
Everything this table leaves out for Aktis Oncology, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the AKTS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full AKTS analysisThe full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysis